18 May 2016 - Suggestion is for drug companies to do antibiotic research or contribute to a common fund to support development of new drugs.

Pharmaceutical companies that don’t invest in their own antibiotic research should contribute to a common fund that would back the development of novel drugs, according to a U.K. government review into the rising threat of superbugs.

The proposed “play-or-pay” model would involve all drugmakers being charged a basic levy by governments. Those that already spend research dollars on their own antibiotic research would either be exempt or could deduct that existing investment from the total. The money raised would fund lump-sum “market-entry bonuses” of around $1 billion to companies that launch novel antibiotics.

For more details, go to: http://www.wsj.com/articles/u-k-proposal-to-fight-drug-resistant-bacteria-has-some-doubters-1463612462?mod=europe&mod=djemITPE_h